Moderna (MRNA) Income from Continuing Operations (2017 - 2026)
Moderna's (MRNA) quarterly Income from Continuing Operations came in at 1343000000.0 in Q1 2026, down 38.31% year-on-year from 2177050083.47 in Q1 2025, and down 62.59% on a QoQ basis from 826000000.0 in Q4 2025.
Moderna (MRNA) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Moderna (MRNA) has 10 years of Income from Continuing Operations data on file, last reported at 1343000000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 38.31% year-over-year to 1343000000.0 in Q1 2026; TTM through Mar 2026 was 3194000000.0, a 4.86% increase from a year earlier, with the FY2025 full-year figure at 2822000000.0, up 20.75% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1343000000.0, down from 826000000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MRNA reached as high as 3657000000.0 in Q1 2022 and fell as low as 3630000000.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 239882352.94 across 5 years, with a median of 825000000.0 in 2025.
- Across the five-year window, Income from Continuing Operations jumped 199.51% in 2022 and slumped 1638.46% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 1465000000.0 in 2022, then sank by 85.19% to 217000000.0 in 2023, then tumbled by 616.13% to 1120000000.0 in 2024, then grew by 26.25% to 826000000.0 in 2025, then sank by 62.59% to 1343000000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 1343000000.0 in Q1 2026, 826000000.0 in Q4 2025, and 200000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Moderna | 22.52 Bn | 17.32 Bn | -566.00 Mn | -1.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.34 Bn |
| Dec 31, 2025 | -826.00 Mn |
| Sep 30, 2025 | -200.00 Mn |
| Jun 30, 2025 | -825.00 Mn |
| Mar 31, 2025 | -971.00 Mn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | -1.28 Bn |
| Mar 31, 2024 | -1.18 Bn |
| Dec 31, 2023 | 217.00 Mn |
| Sep 30, 2023 | -3.63 Bn |
| Jun 30, 2023 | -1.38 Bn |
| Mar 31, 2023 | 79.00 Mn |
| Dec 31, 2022 | 1.47 Bn |
| Sep 30, 2022 | 1.04 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 3.66 Bn |
| Dec 31, 2021 | 4.87 Bn |
| Sep 30, 2021 | 3.33 Bn |
| Jun 30, 2021 | 2.78 Bn |